Entera Bio (ENTX) Change in Cash (2021 - 2026)

Entera Bio has disclosed Change in Cash across 6 years of filings, most recently posting -$3.0 million for Q1 2026.

• Quarterly Change in Cash fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 176.13% YoY) and the FY2025 annual result came in at $6.2 million, up 364.26% from the prior year.
• Change in Cash declined to -$3.0 million in Q1 2026, from -$1.7 million in the prior quarter.
• Over five years, Change in Cash peaked at $11.9 million in Q1 2025 and troughed at -$4.8 million in Q1 2022.
• A 5-year average of -$763941.2 and a median of -$1.7 million in 2025 frame the typical range for Change in Cash.
• Biggest YoY gain for Change in Cash was 750.93% in 2025; the steepest drop was 1337.82% in 2025.
• Tracing ENTX's Change in Cash over 5 years: stood at -$2.0 million in 2022, then surged by 269.27% to $3.4 million in 2023, then sank by 48.75% to $1.7 million in 2024, then plunged by 198.57% to -$1.7 million in 2025, then tumbled by 71.89% to -$3.0 million in 2026.
• Business Quant data shows ENTX's Change in Cash at -$3.0 million in Q1 2026, -$1.7 million in Q4 2025, and -$2.3 million in Q3 2025.